Regeneron Pharmaceuticals, Inc. Revenue & Financials

Regeneron Pharmaceuticals reported total revenues of $14.202 billion for fiscal year 2024, a 9% increase from the $13.117 billion recorded in 2023 and a 17% increase from the $12.173 billion generated in 2022, demonstrating consistent top-line growth despite the maturation of the EYLEA franchise and the increasing competitive pressure from biosimilar entrants. Operating income for 2024 was $3.99 billion, yielding an operating margin of 28.1%, down slightly from 30.9% in 2022 as the company increased R&D spending to support late-stage pipeline programs and expanded manufacturing infrastructure. Net income reached $4.41 billion in 2024, producing a profit margin of 31.1% and diluted earnings per share of $38.34, compared to $34.77 in 2023 and $38.22 in 2022, with the per-share growth reflecting both operational performance and the $3.8 billion returned to shareholders through share repurchases and dividends in 2025. The revenue composition reveals the company's hybrid business model: U.S. net product sales of EYLEA and EYLEA HD contributed $5.97 billion (42% of total), Sanofi collaboration revenue contributed $4.53 billion (32% of total), Bayer collaboration revenue contributed $1.50 billion (10.5% of total), and other products including Libtayo, Praluent, and Kevzara contributed the remaining $2.2 billion. Cash flow from operations remained robust, supporting $18.87 billion in cash and marketable securities against total liabilities of $9.3 billion, with long-term debt at only $1.99 billion and stockholders' equity of $31.26 billion as of December 31, 2025. The company's capital allocation in 2025 included approximately $5.9 billion in R&D investment, $3.8 billion in shareholder returns, and $9 billion committed to manufacturing infrastructure, a spending profile that prioritizes long-term scientific capability over short-term margin expansion. Fourth quarter 2025 revenues of $3.9 billion increased 3% over Q4 2024, with Dupixent profit share from Sanofi reaching $1.49 billion in the quarter alone, up 42% year-over-year, partially offset by a 28% decline in combined EYLEA HD and EYLEA U.S. sales to $1.08 billion. The balance sheet strength provides substantial optionality for business development, with the Decibel acquisition funded from cash and the 2seventy bio transaction requiring only a $5 million upfront payment. Analysts project 2026 revenue of approximately $14.5-$15.0 billion, assuming continued Dupixent growth in COPD and chronic spontaneous urticaria, stabilization of the EYLEA HD transition, and initial contributions from odronextamab and other pipeline assets.